Co‑culture of fibroblast‑like synoviocytes with umbilical cord‑mesenchymal stem cells inhibits expression of pro‑inflammatory proteins, induces apoptosis and promotes chondrogenesis.

The present study aimed to investigate the effect of co‑culture of fibroblast‑like synoviocytes (FLS) with human umbilical cord‑mesenchymal stem cells (UC‑MSCs) on rheumatoid arthritis (RA) and to understand the mechanisms that mediate the induced changes. FLS and UC‑MSCs were isolated and cultured individually, FLS were then cultured with or without UC‑MSCs. The phenotype of UC‑MSCs was analyzed prior to co‑culture. The UC‑MSCs were successfully isolated and expanded, and exhibited a fibroblast‑like morphology. Enzyme‑linked immunosorbent assay (ELISA) and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) were performed to determine the expression levels of interleukin (IL)‑1β, IL‑6, and chemokine (C‑C motif) ligand (CCL)‑2. The cell apoptosis rate was determined by flow cytometry. Furthermore, the RNAs of aggrecan and collagen type II were isolated and assessed in a chondrogenesis assay following co‑culture for 7, 14, 21 and 28 days. Protein expression levels of apoptosis‑related proteins, including B‑cell lymphoma (Bcl‑2), Bcl‑2‑associated X protein, p53 and phospho (p)‑AKT, and growth differentiation factor‑5 were analyzed by western blotting. ELISA and qRT‑PCR demonstrated that compared with FLS cultured alone, co‑culture with UC‑MSCs significantly downregulates the expression levels of IL‑1β, IL‑6 and CCL‑2. Additionally, the percentage of apoptotic cells was significantly increased in the co‑cultured cells (P<0.05), and the relative RNAs levels of aggrecan and collagen type II were increased compared with FLS alone. Furthermore, the expression levels of Bcl‑2 (P<0.05) and p‑AKT (P<0.05) were significantly decreased, whereas, p53 (P=0.001), Bax (P<0.01) and GDF‑5 (P<0.01) were increased by co‑culture of FLS with UC‑MSCs compared with FLS alone. In conclusion, co‑culture of FLS with UC‑MSCs may be important and clinically useful for the treatment of RA by inhibiting the expression of pro‑inflammatory mediators, inducing apoptosis and promoting chondrogenesis.

[1]  C. Bari.  Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys , 2015 .

[2]  C. De Bari.  Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys? , 2015, Arthritis Research & Therapy.

[3]  T. Kvien,et al.  The Burden of Disease in Rheumatoid Arthritis , 2014, PharmacoEconomics.

[4]  T. Vos,et al.  The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study , 2014, Annals of the rheumatic diseases.

[5]  P. Emery,et al.  Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial , 2014, The Lancet.

[6]  P. Proost,et al.  Regulation of TNF‐α with a focus on rheumatoid arthritis , 2013, Immunology and cell biology.

[7]  E. Yannaki,et al.  Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis , 2012, Annals of the rheumatic diseases.

[8]  I. Colmegna,et al.  Current Understanding of Rheumatoid Arthritis Therapy , 2012, Clinical pharmacology and therapeutics.

[9]  Chun Xing Li,et al.  Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. , 2012, Rheumatology.

[10]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[11]  R. Mu,et al.  Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis , 2010, Arthritis Research & Therapy.

[12]  Frederick Wolfe,et al.  Rheumatoid arthritis , 2010, The Lancet.

[13]  J. Rocklöv,et al.  Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. , 2010, Arthritis and rheumatism.

[14]  D. Chang,et al.  GDF-5 is suppressed by IL-1beta and enhances TGF-beta3-mediated chondrogenic differentiation in human rheumatoid fibroblast-like synoviocytes. , 2010, Experimental and molecular pathology.

[15]  Manuel A. González,et al.  Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis , 2009, Annals of the rheumatic diseases.

[16]  Lingyun Sun,et al.  Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and Humans , 2009, Stem cells.

[17]  Iain B McInnes,et al.  Evidence that cytokines play a role in rheumatoid arthritis. , 2008, The Journal of clinical investigation.

[18]  M. Weiss,et al.  Immune Properties of Human Umbilical Cord Wharton's Jelly‐Derived Cells , 2008, Stem cells.

[19]  Erika H. Noss,et al.  The role and therapeutic implications of fibroblast‐like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis , 2008, Immunological reviews.

[20]  E. Jones,et al.  Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies , 2008, Mechanisms of Ageing and Development.

[21]  S. Lehmann,et al.  Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[22]  F. Luyten,et al.  A biomarker-based mathematical model to predict bone-forming potency of human synovial and periosteal mesenchymal stem cells. , 2008, Arthritis and rheumatism.

[23]  R. Tuan,et al.  Comparison of Proliferative and Multilineage Differentiation Potential of Human Mesenchymal Stem Cells Derived from Umbilical Cord and Bone Marrow , 2007, Stem cells.

[24]  R. Cancedda,et al.  Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. , 2007, Arthritis and rheumatism.

[25]  P. Emery,et al.  Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis , 2006, Expert opinion on pharmacotherapy.

[26]  A. Silman,et al.  Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. , 2006, Arthritis and rheumatism.

[27]  K. Fontaine,et al.  Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[28]  G. Burmester,et al.  Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register , 2006, Arthritis research & therapy.

[29]  Qin-jun Zhao,et al.  Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. , 2006, Haematologica.

[30]  Q. Han,et al.  Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. , 2005, Biochemical and biophysical research communications.

[31]  P. Tak,et al.  Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. , 2005, Arthritis and rheumatism.

[32]  A. Silman,et al.  British Society for Rheumatology Biologics Register , 2003, Annals of the rheumatic diseases.

[33]  W. Graninger,et al.  Cartilage-derived morphogenetic protein-1 and -2 are endogenously expressed in healthy and osteoarthritic human articular chondrocytes and stimulate matrix synthesis. , 2002, Osteoarthritis and cartilage.

[34]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[35]  J. Rutter,et al.  Synergistic induction of matrix metalloproteinase 1 by interleukin-1alpha and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism. , 2001, Arthritis and rheumatism.

[36]  O. Sangha.  Epidemiology of rheumatic diseases. , 2000, Rheumatology.

[37]  Shin-Seok Lee,et al.  CD40 Engagement on Synovial Fibroblast Up-Regulates Production of Vascular Endothelial Growth Factor1 , 2000, The Journal of Immunology.

[38]  D. Furst,et al.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. , 1999, Annals of internal medicine.

[39]  I. Ishikawa,et al.  Gene expression of growth and differentiation factors-5, -6, and -7 in developing bovine tooth at the root forming stage. , 1998, Biochemical and biophysical research communications.

[40]  A. Kudo,et al.  Recombinant human growth/differentiation factor 5 stimulates mesenchyme aggregation and chondrogenesis responsible for the skeletal development of limbs. , 1996, Growth factors.

[41]  J. Pohl,et al.  Cloning and expression of recombinant human growth/differentiation factor 5. , 1994, Biochemical and biophysical research communications.

[42]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.